<DOC>
	<DOC>NCT01024400</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity and safety of an inactivated, non adjuvanted A(H1N1)v influenza vaccine in 120 pregnant women. Study procedures will include 2 doses of vaccine, blood samples, cord blood samples at delivery and recording temperature and vaccine side effects in a memory aid for 7 days following each vaccination. Participants will be involved in study related procedures about 3 at 5 months.</brief_summary>
	<brief_title>Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 years to 45 years Pregnancy between 22 and 32 weeks of gestation Provides written informed consent Covered by French Social Security Allergy to eggs or other components in the vaccine History of severe reactions following previous influenza vaccines H1N1 influenza (virologically documented) during the last 6 months Febrile episode within one week prior to vaccination Known HIV, HBV, HCV infection Multiple sclerosis History of GuillainBarr√© syndrome Organ transplant recipient Neoplastic disease in the past 3 years Other vaccine within 3 weeks prior to study entry or planned within the month following the last injection Systemic corticosteroids,immunotherapy,chemotherapy Anticoagulant treatment Immunoglobulin or blood transfusion within the 3 months prior to enrollment in this study History of cardiac disease Chronic liver disease Diabetes before pregnancy History of premature delivery History of eclampsia Fetal morphologic abnormalities</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Pregnancy</keyword>
</DOC>